{"id":946522,"date":"2026-03-24T10:26:54","date_gmt":"2026-03-24T14:26:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/"},"modified":"2026-03-24T10:26:54","modified_gmt":"2026-03-24T14:26:54","slug":"imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/","title":{"rendered":"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <b>LAWRENCEVILLE, N.J., March  24, 2026  (GLOBE NEWSWIRE) &#8212; <\/b><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eB-LXLuOTX6-zCiOt9aR3vZrA0--y7CKKBr39yFyd5cf96Q3iGJwgONl1Q2iDqSNyI7fqb_skf3xpLge5qhugP2m9i89nbcIxBrLIly839y-y19BNuttU_FcEjjqh2Xe15JRGpBZLV0H-cyiPmOXXJb8sUTvE4YDtu2VJD6WjbHNdivUh9j6fMQv_MbLsqm5rbK8YlF_pYKlUnnGwCrD4kP5OyBhAMBVGCmRvTlO-0tD6ENDlXmKdnqT2a3G54FraF6XryCqCZyXRx_YIAz0CTtut8fAp3Gl9n2_l456pvTlIu5x-wJ18p9Ik9pqFHPZGXho_HQj5YCR6YPeLl6OYeYwZJzx_FURVpIIH1KIflM=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <b>IMUNON<\/b><br \/>\n        <\/a><br \/>\n        <b>, Inc. (Nasdaq: IMNN)<\/b>, a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at\u00a011:00 a.m. EDT\u00a0on\u00a0Tuesday, March 31, 2026 to discuss financial results for the year ended\u00a0December 31, 2025,\u00a0and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy.<\/p>\n<p align=\"justify\">The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America\/Toll Free) or 646-307-1963 (U.S.\/Toll) and ask for the IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live webcast of the call will also be available\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tzeg8SfLxxO0mkj8g9lOqdmsq9RUZOSZmlt5bZyhOWYc3QruoR7d-nTjqgvHwEnwW96xcKlbmc2u280n7KIQknmJBX4Fnnh0LWQAi0v9mh4=\" rel=\"nofollow\" target=\"_blank\"><b>here<\/b><\/a>.<\/p>\n<p align=\"justify\">An audio replay of the call will be available for 90 days and can be accessed at 800-770-2030 (U.S.\u00a0and Canada\/Toll Free), 609-800-9909 (U.S.\/Toll) or 647-362-9199 (Canada\/Toll) using replay access code 4157104#.<\/p>\n<p align=\"justify\">\n        <b>About\u00a0IMUNON<\/b>\n      <\/p>\n<p align=\"justify\">IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body\u2019s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas<sup>\u00ae<\/sup>, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine<sup>\u00ae<\/sup>, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.<\/p>\n<p align=\"justify\">The Company\u2019s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BmPbIyhkQv9T-wqmCCW5wxrPBZye9EQ5evJHwsk2EL4VXSnoHHN4yGJuoipv2LU0rn4nfjhe2JkuSsNE-NJ8vu_ZwDgA7GPcWRngPhMSE8mJwk_8sixTFqrn52YstxdjoRkdKdJ0Mg5uMmijk64InnN82KZ5JTQ7Kn_jZfH-rulvejzgszmTKB7RbXxFkUGFVoex5E9qwcWGORHB_BRVs4LHsdY9lS3EwPIqymuI_RA=\" rel=\"nofollow\" target=\"_blank\"><b>www.imunon.com<\/b><\/a>.<\/p>\n<p align=\"justify\">\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">\n        <i>IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company\u2019s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company\u2019s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company\u2019s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as \u201cmay,\u201d \u201cwill,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cestimate,\u201d \u201cintend\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON\u2019s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.<\/i>\n      <\/p>\n<p>\n        <b>Contacts: <\/b>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <b>Media<\/b>\n          <\/td>\n<td style=\"vertical-align: top\">\n            <b>Investors <\/b>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Jenna Urban<\/td>\n<td style=\"vertical-align: top\">Peter Vozzo<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">CG life<\/td>\n<td style=\"vertical-align: top\">ICR Healthcare<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">212-253-8881<\/td>\n<td style=\"vertical-align: top\">443-213-0505<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <a href=\"mailto:jurban@cglife.com\" rel=\"nofollow\" target=\"_blank\"><br \/>\n              <b>jurban@cglife.com<\/b><br \/>\n            <\/a>\n          <\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"mailto:peter.vozzo@icrhealthcare.com\" rel=\"nofollow\" target=\"_blank\"><br \/>\n              <b>peter.vozzo@icrhealthcare.com<\/b><br \/>\n            <\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWY2YmExZDEtODFiOC00ODlmLTk2ZmMtMmQ0YjM2Yzk0ZGZmLTUwMDA0OTc3Ni0yMDI2LTAzLTI0LWVu\/tiny\/Imunon-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) &#8212; IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at\u00a011:00 a.m. EDT\u00a0on\u00a0Tuesday, March 31, 2026 to discuss financial results for the year ended\u00a0December 31, 2025,\u00a0and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America\/Toll Free) or 646-307-1963 (U.S.\/Toll) and ask for the IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-946522","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) &#8212; IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at\u00a011:00 a.m. EDT\u00a0on\u00a0Tuesday, March 31, 2026 to discuss financial results for the year ended\u00a0December 31, 2025,\u00a0and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America\/Toll Free) or 646-307-1963 (U.S.\/Toll) and ask for the IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live &hellip; Continue reading &quot;IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-24T14:26:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026\",\"datePublished\":\"2026-03-24T14:26:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/\"},\"wordCount\":693,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/\",\"name\":\"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==\",\"datePublished\":\"2026-03-24T14:26:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/","og_locale":"en_US","og_type":"article","og_title":"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - Market Newsdesk","og_description":"LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) &#8212; IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a conference call at\u00a011:00 a.m. EDT\u00a0on\u00a0Tuesday, March 31, 2026 to discuss financial results for the year ended\u00a0December 31, 2025,\u00a0and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy. The Company is hosting a conference call to review 2025 financial results and provide a business update on March 31, 2026 at 11:00 a.m. EDT. To participate in the call, please dial 800-715-9871 (North America\/Toll Free) or 646-307-1963 (U.S.\/Toll) and ask for the IMUNON Year End 2025 Financial Results Call (Conference ID 4157104). A live &hellip; Continue reading \"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-03-24T14:26:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026","datePublished":"2026-03-24T14:26:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/"},"wordCount":693,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/","name":"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==","datePublished":"2026-03-24T14:26:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY3NzE5NyM3NDk5ODAxIzUwMDA0OTc3Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/imunon-to-hold-2025-financial-results-and-business-update-conference-call-on-tuesday-march-31-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946522","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=946522"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/946522\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=946522"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=946522"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=946522"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}